Posology : מינונים

4.2 Posology and method of administration
Posology
The usual dosage is one intramuscular injection of Decapeptyl Depot 3.75mg every month under medical supervision.
Central Precocious Puberty: Initially, 3.75 mg on days 0, 14, 28 and then 3.75 mg every 28 days. If the effect is insufficient, injections may be given every 21 days. Dosing should be based on body weight. Children weighing less than 20 kg are injected with 1.875 mg (half-dose), children between 20 and 30 kg receive 2.5 mg (2/3 dose), and children weighing more than 30 kg are injected with 3.75 mg (full dose). Treatment should be stopped if a bone maturation of older than 12 years in girls and older than 13 years in boys has been achieved.
Breast cancer
The content from a vial, equal 3.75 mg triptorelin, is injected intramuscularly once a month (every 4 weeks) in combination with tamoxifen or an aromatase inhibitor (AI).
Triptorelin should be commenced after completion of chemotherapy, once pre-menopausal status has been confirmed.
Treatment with triptorelin must be initiated at least 6-8 weeks before starting aromatase inhibitor treatment. A minimum of two injections of triptorelin (with an interval of 4 weeks between injections) should be administered before commencement of aromatase inhibitor treatment.
During treatment with an aromatase inhibitor, triptorelin must not be interrupted to avoid rebound increases in circulating oestrogens in pre-menopausal women.
The recommended treatment duration for adjuvant treatment in combination with other hormonotherapy is up to 5 years.
Treatment monitoring
Men: For treatment monitoring, PSA and testosterone in serum should be determined. After an initial increase in serum testosterone reaches castration level after 2-4 weeks and remains as long as the treatment continues. Transient increase in the amount of acidic phosphatase occurs sometimes in the early stages but has generally returned to normal or near normal values during the 4th week.
Female: Pregnancy should be excluded before starting treatment.
Special dosage recommendations
Elderly patients: The dose does not have to be adapted to age.
The medicine is not indicated for post-menopausal women.
Patients with renal or hepatic impairment
No dosage adjustment is necessary for patients with renal or hepatic impairment.

Method of administration
Precautions to be taken before handling or administrating the medicinal product.
As with other medicinal products administered by injection, the injection site should be varied periodically.
Since Decapeptyl depot 3.75mg is a suspension of microgranules, inadvertent intravascular injection must be strictly avoided.
The injection of Decapeptyl depot 3.75mg is administered by health care professionals.
For instructions on reconstitution of the medicinal product before administration, see section 6.6.